Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer | Zendy

Federico Innocenti | Zendy; Richard L. Schilsky | Zendy; Jacqueline Ramı́rez | Zendy; Linda Janisch | Zendy; Samir D. Undevia | Zendy; Larry House | Zendy; Soma Das | Zendy; Kehua Wu | Zendy; Michelle Turcich | Zendy; Robert de Wilton Marsh | Zendy; Theodore Karrison | Zendy; Michael L. Maitland | Zendy; Ravi Salgia | Zendy; Mark J. Ratain | Zendy

Open Access

Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer

Author(s) -

Federico Innocenti,

Richard L. Schilsky,

Jacqueline Ramı́rez,

Linda Janisch,

Samir D. Undevia,

Larry House,

Soma Das,

Kehua Wu,

Michelle Turcich,

Robert de Wilton Marsh,

Theodore Karrison,

Michael L. Maitland,

Ravi Salgia,

Mark J. Ratain

Publication year - 2014

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2014.55.2307

Subject(s) - irinotecan , medicine , genotype , pharmacokinetics , dosing , neutropenia , gastroenterology , sn 38 , pharmacodynamics , toxicity , cancer , pharmacology , colorectal cancer , biology , biochemistry , gene

The risk of severe neutropenia from treatment with irinotecan is related in part to UGT1A1*28, a variant that reduces the elimination of SN-38, the active metabolite of irinotecan. We aimed to identify the maximum-tolerated dose (MTD) and dose-limiting toxicity (DLT) of irinotecan in patients with advanced solid tumors stratified by the *1/*1, *1/*28, and *28/*28 genotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research